Renal impairment, including with end-stage renal disease (ESRD):.Indicated to reduce the risk of recurrent DVT and PE following initial 6 months treatment for DVT and/or PE.10 mg orally twice daily for 7 days, then 5 mg twice daily.Indicated for treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE).Deep Vein Thrombosis: No dose adjustment recommended clinical efficacy and safety studies did not enroll patients with ESRD on dialysis or patients with a CrCl less than 15 mL/min dosing recommendations are based on pharmacokinetic and pharmacodynamic (anti-FXa activity) data in study subjects with ESRD maintained on dialysis.Renal impairment, including with end-stage renal disease ( ESRD) on dialysis:.Duration of therapy (knee replacement): 2.5 mg orally twice daily for 12 days.Duration of therapy (hip replacement): 2.5 mg orally twice daily for 35 days.Initial: Give 2.5 mg orally 12-24 hours after surgery.Indicated following hip or knee replacement surgery.Indicated to reduce risk of stroke and systemic embolism associated with nonvalvular atrial fibrillation.Stroke Prophylaxis with Atrial Fibrillation Dosage Considerations – Should be Given as Follows:
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |